Company: BLTE
Filing Date: 2025-12-02
Form Type: 424B5
Source: 0001104659-25-117702
Chunk: 64

Company: BELITE BIO, INC
Filing Date: 2025-12-02
Form: 424B5
Chunk 64
---
 of the lock-up party or the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of ADSs or ordinary shares may be made under such plan during the restricted period,

•

the sale of ADSs or ordinary shares pursuant to an existing trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that to the extent a public announcement or filing under the Exchange Act is required of the lock-up party or the Company regarding the sale, such announcement or filing shall include a statement to the effect that the sale occurred pursuant to such trading plan;

•

the transfer of ADSs or ordinary shares or any security convertible into or exercisable or exchangeable for ADSs pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company, made to all holders of ADSs or ordinary shares involving a Change of Control (as defined below), provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the ADSs or ordinary shares owned by the lock-up party shall remain subject to the same restrictions. For the purposes of this clause, “Change of Control” means the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an pursuant to this offering), of the Company’s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 75% of the outstanding voting securities of the Company (or the surviving entity);

•

(i) the receipt by the lock-up party from the Company of ADSs or ordinary shares upon the exercise of options or warrants, insofar as such options or warrants are outstanding as of the date of the Prospectus, provided that such options or warrants are described in the Prospectus and the Securities received upon exercise of such option or warrant shall remain subject to this agreement or (ii) the transfer of ADSs or ordinary shares or any securities convertible into ADSs or ordinary shares to the Company upon a vesting event of the Company’s securities or upon the exercise of options or warrants to purchase the Company’s securities on a “cashless” or “net exercise” basis to the extent permitted by the instruments representing such options or warrants so long as such “cashless” exercise or “net exercise” is effected solely by the surrender of outstanding options or warrants to the Company and the Company